Previewing Packaging Innovations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Previewing Packaging Innovations
The annual INTERPHEX show presents end-to-end packaging solutions.


Pharmaceutical Technology
Volume 37, Issue 4, pp. 68-70

Anticounterfeiting and tamper evidence


Figure 2: An AlpVision app enables product authentication via smartphone. FIGURE 2 COURTESY OF ALPVISION
Smartphones help fight counterfeiting with an app designed to authenticate products in three seconds. As shown in Figure 2, the phone is positioned over packaging or molded parts to detect and verify covert safety features (e.g., taggants or microprinting, which looks like part of the graphics but reveals a message when examined under magnification). The verification action also can deliver information to the user/consumer about product features, user data, and market (smartphone authentication app for Cryptoglyph and Fingerprint covert safety features, AlpVision).


Figure 3: Schreiner MediPharm’s Pharma-Comb Security Label helps prevent counterfeiting. FIGURE 3 COURTESY OF SCHREINER MEDIPHARM
Schreiner MediPharm’s peel-off label for vials now includes a security version with overt and/or covert features to authenticate product and help prevent counterfeiting (see Figure 3). The mix of security elements can be customized and often can be added without changing the label design. Options include overt elements, such as holograms, color-shifting security inks, and guilloche patterns, as well as covert tools, such as voiding effects and LaserSecure, which relies on pigments that only can be “seen” by a dedicated handheld reader. The label also incorporates detachable segments for patient record updating and other purposes. For extra security, removal of detachable sections from the substrate reveals the message, “peel-off part has been removed” (Pharma-Comb Security Label, Schreiner MediPharm).

Another anticounterfeiting tool, a proprietary, two-dimensional barcode from Complete Inspection Systems, matches and verifies GS1 codes printed during packaging operations. The data-intensive barcode can provide information about the location of covert codes used for product authentication (HD P.A.S.S. Barcode Solution, Complete Inspection Systems).


Figure 4: A carton from RondoPak has a tamper-evident design. FIGURE 4 COURTESY OF KÖRBER MEDIPAK.
Rondo-Pak’s tamper-evident carton design opens and recloses as easily as a standard folding carton and can be erected and loaded at the same speed as a conventional folding carton (see Figure 4). Perforations cause the lid and dust flaps to tear. The design reportedly surpasses first-opening verification security requirements of the Falsified Medicines Directive 2011/62/EU, which take effect in 2016 (tamper-evident folding carton, Rondo-Pak).

Quality control technology


Figure 5: Pharma Technology’s AIO All In One Deduster and Tester System measures tablet characteristics. FIGURE 5 COURTESY OF PHARMA TECHNOLOGY.
A quiet (less than 70 decibels), compact tablet-deduster and testing system from Pharma Technology combines multiple functions such as segmented deduster spirals and metal detector on one base (see Figure 5). The high precision, in-process tablet tester checks weight, hardness, and thickness by sampling at regular intervals and feeds test data to the tablet press for recording into the batch record. Testers can be positioned on three sides of the base and offer push-fit, cable-free connections for power and data storage. A washable, exchangeable deduster module minimizes changeover time (AIO All In One Deduster and Tester System, Pharma Technology).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here